AZGP1 Up-Regulation is a Potential Target for Andrographolide Reversing Radioresistance of Colorectal Cancer

Background Radiation resistance is a challenge that limits the therapeutic benefit of colorectal cancer (CRC) treatment, but the mechanism underlying CRC radiation resistance remains unclear. Andrographolide shows a broad-spectrum anti-tumor effect in various malignancies, including CRC, its effect and how it functions in CRC initiation, and radiation have not been established. This study aimed to explore the mechanism of CRC radiation resistance and the potential mechanisms of andrographolide on CRC radiation. Methods Two acquired radioresistant cell lines were established and high throughput sequencing was employed to screen out the differentially expressed genes. The expression of AZGP1, which was upregulated in the acquired radioresistant tissues, was verified by microarray data recomputing. The common targets of andrographolide, CRC initiation, and radiation resistance were obtained, and the corresponding functional enrichment and pathway analysis were performed. The interaction between AZGP1 and andrographolide was investigated using molecular docking. Results AZGP1 was upregulated in both the radioresistant cell model and microarray data. Moreover, AZGP1 was upregulated in cancerous colorectal tissue and displayed a tendency toward elevated expression in patients with an unfavorable prognosis. AZGP1 was identified as the common target of andrographolide, colorectal cancer initiation, and radiotherapy resistance. Ultimately, the protein structure of AZGP1 proved to be closely intertwined with the crystal texture of andrographolide. Conclusion AZGP1 is recognized as a crucial factor for both CRC initiation and radioresistance. Andrographolide may affect the radioresistance of CRC via the targeting of AZGP1. Thus, the combination of andrographolide and AZGP1 intervention might be a promising strategy for improving the treatment benefit of CRC radiotherapy.

[1]  Hong Yang,et al.  LPCAT1 overexpression promotes the progression of hepatocellular carcinoma , 2021, Cancer Cell International.

[2]  Yongsheng Si,et al.  Andrographolide and its derivatives: Current achievements and future perspectives. , 2021, European journal of medicinal chemistry.

[3]  Wei Zhang,et al.  Andrographolide Against Lung Cancer-New Pharmacological Insights Based on High-Throughput Metabolomics Analysis Combined with Network Pharmacology , 2021, Frontiers in Pharmacology.

[4]  R. Suárez-Sánchez,et al.  Deciphering the epigenetic network in cancer radioresistance. , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  Xianguo Zhou,et al.  Clinical significance and molecular mechanism of angiotensin-converting enzyme 2 in hepatocellular carcinoma tissues , 2021, Bioengineered.

[6]  M. Faisal,et al.  Andrographolide Induces Apoptosis and Cell Cycle Arrest through Inhibition of Aberrant Hedgehog Signaling Pathway in Colon Cancer Cells , 2020, Nutrition and Cancer.

[7]  K. Cao,et al.  Andrographolide enhanced radiosensitivity by downregulating glycolysis via the inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 colorectal cancer cells , 2020, The Journal of international medical research.

[8]  I. Khan,et al.  Andrographolide Inhibits Proliferation of Colon Cancer SW-480 Cells via Downregulating Notch Signaling Pathway. , 2020, Anti-cancer agents in medicinal chemistry.

[9]  Ting Liu,et al.  AZGP1 suppresses the process of colorectal cancer after upregulating FASN expression via mTOR signal pathway. , 2020, General physiology and biophysics.

[10]  Huanming Yang,et al.  An atlas of the protein-coding genes in the human, pig, and mouse brain , 2020, Science.

[11]  I. Khan,et al.  Antiproliferative and apoptotic property of andrographolide against human colon cancer DLD1 cell line. , 2019, Endocrine, metabolic & immune disorders drug targets.

[12]  B. Lai,et al.  Elemental Zn and its Binding Protein Zinc-α2-Glycoprotein are Elevated in HPV-Positive Oropharyngeal Squamous Cell Carcinoma , 2019, Scientific Reports.

[13]  Jianming Xu,et al.  Zinc-α2-glycoprotein 1 promotes EMT in colorectal cancer by filamin A mediated focal adhesion pathway , 2019, Journal of Cancer.

[14]  S. Nanduri,et al.  Andrographolide: A natural product template for the generation of structurally and biologically diverse diterpenes. , 2019, European journal of medicinal chemistry.

[15]  Weicheng Wang,et al.  Andrographolide sensitizes Hep-2 human laryngeal cancer cells to carboplatin-induced apoptosis by increasing reactive oxygen species levels. , 2019, Anti-cancer drugs.

[16]  I. Petkovska,et al.  Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy , 2019, JAMA oncology.

[17]  Nuno A. Fonseca,et al.  ArrayExpress update – from bulk to single-cell expression data , 2018, Nucleic Acids Res..

[18]  L. Livi,et al.  Combination of novel systemic agents and radiotherapy for solid tumors - Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity. , 2019, Critical reviews in oncology/hematology.

[19]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[20]  Xiaochi Ma,et al.  Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway , 2018, Journal of experimental & clinical cancer research : CR.

[21]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[22]  Wanyin Wu,et al.  Application of Traditional Chinese Medicines as Personalized Therapy in Human Cancers. , 2018, The American journal of Chinese medicine.

[23]  Ahmed Kamel,et al.  Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[24]  L. Kachnic,et al.  Evolving Treatment Paradigm in the Treatment of Locally Advanced Rectal Cancer. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[25]  I. Khan,et al.  Andrographolide Exhibits Anticancer Potential Against Human Colon Cancer Cells by Inducing Cell Cycle Arrest and Programmed Cell Death via Augmentation of Intracellular Reactive Oxygen Species Level , 2018, Nutrition and cancer.

[26]  W. Meng,et al.  Andrographolide Antagonizes TNF-α-Induced IL-8 via Inhibition of NADPH Oxidase/ROS/NF-κB and Src/MAPKs/AP-1 Axis in Human Colorectal Cancer HCT116 Cells. , 2018, Journal of agricultural and food chemistry.

[27]  N. Kim,et al.  Contemporary management of locally advanced rectal cancer: Resolving issues, controversies and shifting paradigms. , 2018, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[28]  J. Ji,et al.  AZGP1 inhibits soft tissue sarcoma cells invasion and migration , 2018, BMC Cancer.

[29]  Yuze Chen,et al.  Andrographolide enhanced 5-fluorouracil-induced antitumor effect in colorectal cancer via inhibition of c-MET pathway , 2017, Drug design, development and therapy.

[30]  Qiang Xu,et al.  Andrographolide enhances cisplatin-mediated anticancer effects in lung cancer cells through blockade of autophagy , 2017, Anti-cancer drugs.

[31]  Ying Liu,et al.  Neuronal zinc-α2-glycoprotein is decreased in temporal lobe epilepsy in patients and rats , 2017, Neuroscience.

[32]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[33]  G. Wang,et al.  Andrographolide Inhibits Proliferation and Metastasis of SGC7901 Gastric Cancer Cells , 2017, BioMed research international.

[34]  Han Li,et al.  Zinc alpha2 glycoprotein alleviates palmitic acid-induced intracellular lipid accumulation in hepatocytes , 2017, Molecular and Cellular Endocrinology.

[35]  Qiming Wang,et al.  Reduction of AZGP1 predicts poor prognosis in esophageal squamous cell carcinoma patients in Northern China , 2016, OncoTargets and therapy.

[36]  Haiyang Xie,et al.  Downregulation of AZGP1 by Ikaros and histone deacetylase promotes tumor progression through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma , 2016, Carcinogenesis.

[37]  Qiang Xu,et al.  Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression. , 2016, Biochemical pharmacology.

[38]  J. Kench,et al.  Loss of AZGP1 as a Superior Predictor of Relapse in Margin‐Positive Localized Prostate Cancer , 2016, The Prostate.

[39]  P. Carroll,et al.  Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi‐Institutional Radical Prostatectomy Cohort , 2016, The Prostate.

[40]  M. Lan,et al.  Synergistic anticancer effects of andrographolide and paclitaxel against A549 NSCLC cells , 2016, Pharmaceutical biology.

[41]  Ting Liu,et al.  AZGP1 suppresses epithelial-to-mesenchymal transition and hepatic carcinogenesis by blocking TGFβ1-ERK2 pathways. , 2016, Cancer letters.

[42]  T. Choudhuri,et al.  Cytotoxicity and cell cycle arrest induced by andrographolide lead to programmed cell death of MDA-MB-231 breast cancer cell line , 2016, Journal of Biomedical Science.

[43]  Yan Guo,et al.  Andrographolide inhibits growth of human T-cell acute lymphoblastic leukemia Jurkat cells by downregulation of PI3K/AKT and upregulation of p38 MAPK pathways , 2016, Drug design, development and therapy.

[44]  G. Sonpavde,et al.  Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors , 2016, Cell cycle.

[45]  G. Sauter,et al.  Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG‐fusion positive and PTEN deleted prostate cancers , 2016, International journal of cancer.

[46]  JianRong Wang,et al.  Andrographolide inhibits multiple myeloma cells by inhibiting the TLR4/NF-κB signaling pathway. , 2016, Molecular medicine reports.

[47]  H. Gu,et al.  Effects of sitagliptin on circulating zinc-α2-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial. , 2015, European journal of endocrinology.

[48]  L.P. Xu,et al.  Andrographolide radiosensitizes human esophageal cancer cell line ECA109 to radiation in vitro. , 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[49]  H. Haller,et al.  Zinc-α2-Glycoprotein Exerts Antifibrotic Effects in Kidney and Heart. , 2015, Journal of the American Society of Nephrology : JASN.

[50]  Hongchuan Jiang,et al.  Andrographolide inhibits hypoxia-inducible factor-1 through phosphatidylinositol 3-kinase/AKT pathway and suppresses breast cancer growth , 2015, OncoTargets and therapy.

[51]  P. Chaudhari,et al.  Enhanced hepatoprotective activity of andrographolide complexed with a biomaterial , 2015, Drug delivery.

[52]  Wei Zhou,et al.  TCMSP: a database of systems pharmacology for drug discovery from herbal medicines , 2014, Journal of Cheminformatics.

[53]  Sean R. Davis,et al.  NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..

[54]  Wei Chen,et al.  Andrographolide induces autophagic cell death in human liver cancer cells through cyclophilin D-mediated mitochondrial permeability transition pore. , 2012, Carcinogenesis.

[55]  Andrew E. Jaffe,et al.  Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .

[56]  Xuesong Yang,et al.  Andrographolide Inhibits Oral Squamous Cell Carcinogenesis through NF-κB Inactivation , 2011, Journal of dental research.

[57]  L. Gordon,et al.  Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculata , 2010, Clinical Cancer Research.

[58]  Li-xi Yang,et al.  Novel chemoradiosensitizers for cancer therapy. , 2010, Anticancer research.

[59]  Yi-Chieh Lee,et al.  Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway. , 2010, European journal of pharmacology.

[60]  David M Holtzman,et al.  Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease , 2007, Proteomics. Clinical applications.

[61]  J. Turchi,et al.  Cisplatin Sensitizes Cancer Cells to Ionizing Radiation via Inhibition of Nonhomologous End Joining , 2005, Molecular Cancer Research.

[62]  C. López-Otín,et al.  Human Zn-alpha 2-glycoprotein: complete genomic sequence, identification of a related pseudogene and relationship to class I major histocompatibility complex genes. , 1993, Genomics.

[63]  P M Moodie,et al.  COHORT , 1971, The Medical journal of Australia.